<DOC>
	<DOC>NCT03035591</DOC>
	<brief_summary>This is a first-in-man study to assess the safety and tolerability and to characterise the pharmacokinetics of ODM-207.</brief_summary>
	<brief_title>ODM-207 in Patients With Advance Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Patients with histologically or cytologically confirmed locally advanced or metastatic cancer for which no effective standard therapy exists or are refractory or resistant to conventional therapy Life expectancy &gt;12 weeks Patient may have either measurable or nonmeasurable disease, but must have disease that can be evaluated for improvement of progression ECOG performance status of 0 to 1 History of bleeding disorder or significant bleeding episode within 6 months prior to study treatment Subjects receiving anticoagulants or medications that durably inhibit platelet function (7day washout prior to study treatment) History of or current leptomeningeal or brain metastasis or spinal cord compression.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>